BI 3802876 Clinical Trials (2026): 2 Studies for Healthy & Liver Cirrhosis
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
2 BI 3802876 clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 2 indications (including Healthy & Liver Cirrhosis) and 88 total planned enrollment. 1 BI 3802876 clinical trial is actively recruiting at 1 U.S. site across 1 state. Most recent activity: NCT07325526 (Jul 2027).
Where to Participate: All BI 3802876 Trial Sites in the U.S. (1 site across 1 state)
Every actively recruiting BI 3802876trial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| TX | American Research Corporation at the Texas Liver Institute | San Antonio78215 | NCT07325526 | Map |
BI 3802876 clinical trials at a glance: phase × recruitment status
| Phase | recruiting | completed | Total |
|---|---|---|---|
| P1 | 1 | 1 | |
| P2 | 1 | 1 |
Recruiting BI 3802876 clinical trials (1)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT07325526 | MASHA Study to Test Whether BI 3802876 is Tolerated in People With Compensated Liver Cirrhosis Due to Metabolic Dysfunction- Associated Steatohepatitis (MASH) | P2 | Liver Cirrhosis | 29 | Feb 2026 |
BI 3802876 clinical trials by indication
Liver Cirrhosis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07325526 | MASH | P2 | recruiting | A Study to Test Whether BI 3802876 is Tolerated in People With Compensated Liver Cirrhosis Due to Metabolic Dysfunction- Associated Steatohepatitis (MASH) |
Healthy (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06081530 | — | P1 | completed | A Study in Healthy Men to Test How Well Different Doses of BI 3802876 Are Tolerated |
BI 3802876 pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| MASH | NCT07325526 | P2 | recruiting | Liver Cirrhosis | 29 | — |
All BI 3802876 trials (2)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT07325526 | MASH | A Study to Test Whether BI 3802876 is Tolerated in People With Compensated Liver Cirrhosis Due to Metabolic Dysfunction- Associated Steatohepatitis (MASH) | P2 | recruiting | 29 | Boehringer Ingelheim | Feb 2026 |
| NCT06081530 | A Study in Healthy Men to Test How Well Different Doses of BI 3802876 Are Tolerated | P1 | completed | 59 | Boehringer Ingelheim | Oct 2023 |
BI 3802876 clinical trials: frequently asked questions
- How many BI 3802876 clinical trials are there?
- 2 BI 3802876 clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 1 is actively recruiting participants. 1 is marked completed.
- Are BI 3802876 clinical trials recruiting in 2026?
- Yes — 1 BI 3802876 trial is actively recruiting in 2026, with 1 U.S. site across 1 state. See the recruiting trials and the per-state site list further down this page.
- What conditions is BI 3802876 being studied for?
- BI 3802876 is being studied for Healthy, Liver Cirrhosis. The trials are grouped by indication on this page.
- What phase is BI 3802876 in?
- BI 3802876 clinical trials span 1 Phase 2, 1 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors BI 3802876 clinical trials?
- The lead sponsor across the most BI 3802876 trials is Boehringer Ingelheim. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming BI 3802876as an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: